This HTML5 document contains 58 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00617/identifier/wikipedia/
foafhttp://xmlns.com/foaf/0.1/
n8http://linked.opendata.cz/resource/drugbank/company/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00617/identifier/pharmgkb/
n12http://linked.opendata.cz/resource/drugbank/drug/DB00617/identifier/kegg-compound/
n11http://linked.opendata.cz/resource/drugbank/drug/DB00617/identifier/pubchem-compound/
n20http://bio2rdf.org/drugbank:
n10http://linked.opendata.cz/resource/drugbank/drug/DB00617/identifier/pubchem-substance/
n13http://linked.opendata.cz/resource/drugbank/drug/DB00617/identifier/kegg-drug/
admshttp://www.w3.org/ns/adms#
n19http://www.drugs.com/mtm/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00617/identifier/drugbank/
n17http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
n14http://linked.opendata.cz/resource/drugbank/drug/DB00617/identifier/chemspider/
xsdhhttp://www.w3.org/2001/XMLSchema#
n6http://linked.opendata.cz/resource/atc/
n5http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00617
rdf:type
n3:Drug
n3:description
Paramethadione is an anticonvulsant in the oxazolidinedione class. It is associated with fetal trimethadione syndrome, which is also known as paramethadione syndrome.
n3:generalReferences
# Hoffman DJ, Chun AH: Paramethadione and metabolite serum levels in humans after a single oral paramethadione dose. J Pharm Sci. 1975 Oct;64(10):1702-3. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/1185541 # Feldman GL, Weaver DD, Lovrien EW: The fetal trimethadione syndrome: report of an additional family and further delineation of this syndrome. Am J Dis Child. 1977 Dec;131(12):1389-92. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/412416
n3:group
approved
n3:halfLife
12 to 24 hours (however the half-life for the active metabolite is not known)
n3:indication
Used for the control of absence (petit mal) seizures that are refractory to treatment with other medications.
n3:manufacturer
n8:271B56FD-363D-11E5-9242-09173F13E4C5
owl:sameAs
n17:DB00617 n20:DB00617
dcterms:title
Paramethadione
adms:identifier
n10:46509173 n11:8280 n12:C07411 n13:D00495 n14:7979 n15:DB00617 n21:PA164748880 n22:Paramethadione
n3:mechanismOfAction
Dione anticonvulsants such as paramethadione reduce T-type calcium currents in thalamic neurons (including thalamic relay neurons). This inhibits corticothalamic transmission and raises the threshold for repetitive activity in the thalamus. This results in a dampening of the abnormal thalamocortical rhythmicity proposed to underlie the 3-Hz spike-and-wave discharge seen on electroencephalogram (EEG) during absence seizures.
n3:synonym
Paramethadione Parametadione Paradione Paramethadionum Parametadiona
n3:toxicity
Symptoms of overdose include clumsiness or unsteadiness, coma, severe dizziness, severe drowsiness, severe nausea, and problems with vision.
n3:proteinBinding
Not significant
foaf:page
n19:paramethadione.html
n3:IUPAC-Name
n4:271B5702-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B5708-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B5707-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B5704-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B5705-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B5706-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B5700-363D-11E5-9242-09173F13E4C5 n4:271B5716-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B56FE-363D-11E5-9242-09173F13E4C5 n4:271B5701-363D-11E5-9242-09173F13E4C5 n4:271B5718-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B56FF-363D-11E5-9242-09173F13E4C5
n5:hasATCCode
n6:N03AC01
n3:H-Bond-Acceptor-Count
n4:271B570E-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B570F-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B5709-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B570A-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B570C-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B570B-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B570D-363D-11E5-9242-09173F13E4C5
n3:absorption
Rapid via the digestive tract.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
115-67-3
n3:Bioavailability
n4:271B5712-363D-11E5-9242-09173F13E4C5
n3:Boiling-Point
n4:271B5717-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B5714-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B5715-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B5711-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B5710-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B5713-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B5703-363D-11E5-9242-09173F13E4C5